What is CUSIP 761330109?

CUSIP 761330109 is the security identifier used in SEC filing datasets for RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share.

Security Snapshot

Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) Institutional Ownership

Q: Who owns RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

CUSIP: 761330109

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$3.65

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock, par value $0.001 per share
Symbol: RVNC
Shares outstanding: 104,661,494
SEC-reported price per share: $3.65

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Key facts

RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 761330109.
Latest finished 13F holder period is not available.
3 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
SEC-reported value moved from $899,713 to $0.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

761330109

Latest holder period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

RVNC full holder history Revance Therapeutics, Inc. SEC filings Revance Therapeutics, Inc. company facts Revance Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 761330109:

Q4 2025 (0 holders) Q3 2025 (1 holder) Q2 2025 (0 holders) Q1 2025 (1 holder) Q4 2024 (169 holders) Q3 2024 (197 holders) Q2 2024 (167 holders) Q1 2024 (182 holders) Q4 2023 (188 holders) Q3 2023 (184 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

RVNC

Filer	Ownership	Change %	Holdings Value	Nb Shares	Change %	Reporting Name	Report Period
Teoxane SA	6.2%	0%	$32,335,404	6,550,800	0%	Teoxane SA	30 Jan 2025
FRANKLIN RESOURCES INC	4.6%		$23,617,550	4,784,658		Franklin Resources, Inc.	30 Sep 2024
Palo Alto Investors LP	1.5%		$7,955,942	1,611,787		Patrick Lee, MD	30 Sep 2024

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Latest

n/a

Rows shown

1-25 of 48

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	0	$0	-$899,713			$3.65	0
2025 Q3	173,355	$899,713	+$899,713			$5.19	1
2025 Q2	0	$0	-$425,556			$3.65	0
2025 Q1	86,100	$425,000	-$246,196,147	$0	$0	$4.94	1
2024 Q4	81,619,644	$248,123,678	-$34,475,559	$16,655,248	$6,778,042	$3.04	169
2024 Q3	82,760,696	$429,420,057	+$74,534,872	$4,635,708	$3,531,954	$5.19	197
2024 Q2	81,357,406	$209,091,543	-$16,845,100	$329,731	$950,129	$2.57	167
2024 Q1	83,208,743	$409,387,692	+$36,028,524	$2,085,096	$3,225,060	$4.92	182
2023 Q4	72,393,492	$636,347,111	-$60,448,695	$2,724,818	$13,647,354	$8.79	188
2023 Q3	77,847,333	$892,932,350	-$137,486,235	$7,060,932	$11,976,974	$11.47	184
2023 Q2	81,758,941	$2,069,347,401	+$120,257,967	$12,444,984	$26,535,763	$25.31	211
2023 Q1	76,516,583	$2,464,233,089	+$117,647,825	$13,624,226	$45,512,682	$32.21	215
2022 Q4	73,838,140	$1,363,055,604	+$97,419,982	$49,574,470	$141,205,908	$18.46	189
2022 Q3	67,635,567	$1,824,203,436	+$329,402,349	$83,571,000	$213,963,000	$27.00	178
2022 Q2	56,025,691	$774,315,063	+$10,576,060	$9,342,000	$11,006,000	$13.82	156
2022 Q1	54,547,989	$1,063,491,136	+$29,861,073	$7,866,000	$21,589,000	$19.50	149
2021 Q4	52,976,629	$864,638,987	-$84,608,748	$9,592,800	$7,702,000	$16.32	143
2021 Q3	54,870,424	$1,528,696,909	+$20,536,734	$10,409,000	$4,540,000	$27.86	155
2021 Q2	54,097,996	$1,601,222,557	-$17,874,204	$11,195,000	$5,262,000	$29.64	159
2021 Q1	54,835,912	$1,532,629,456	+$56,326,804	$8,899,000	$9,169,000	$27.95	148
2020 Q4	52,750,406	$1,494,882,254	+$97,410,291	$12,834,000	$4,861,000	$28.34	150
2020 Q3	49,472,050	$1,246,067,821	-$26,647,818	$10,415,000	$6,984,000	$25.14	151
2020 Q2	50,606,433	$1,234,538,861	+$33,125,299	$841,000	$4,269,000	$24.42	138
2020 Q1	49,442,358	$731,960,359	-$26,411,053	$711,000	$992,000	$14.80	126
2019 Q4	51,033,735	$828,265,787	+$132,605,351	$1,892,000	$1,404,000	$16.23	130